The company recently merged with BioClonetics and plans to develop treatments for HIV and COVID-19. However, there are no revenues and its Bulgarian partner denies that Enzolytics has a stake in it. Enzolytics has a valuation of $982.1 million but I don’t think the business...
Enzolytics, Inc. owns licensing rights of the Irreversible Pepsin Fraction peptide molecule for the treatment of HIV/AIDS. The company's treatment appears to be different from other treatments. Enzolytics Inc. claims to be offering a product with zero toxicity issues, minor side effec...